蔡尚,田野,徐波.放射治疗联合阻断PD-1/PD-L1通路肿瘤免疫治疗的新进展[J].中华放射医学与防护杂志,2016,36(3):235-240
放射治疗联合阻断PD-1/PD-L1通路肿瘤免疫治疗的新进展
Recent progress in the combination treatment of radiotherapy and PD-1/PD-L1 signaling blockade immunotherapy
投稿时间:2015-09-29  
DOI:10.3760/cma.j.issn.0254-5098.2016.03.015
中文关键词:  放疗  PD-1/PD-L1通路  肿瘤免疫治疗
英文关键词:Radiotherapy  PD-1/PD-L1 signal blockade  Oncology immunotherapy
基金项目:
作者单位E-mail
蔡尚 215004 苏州大学附属第二医院肿瘤放射治疗科 苏州大学肿瘤放射治疗学研究所 苏州市肿瘤放射治疗学重点实验室  
田野 215004 苏州大学附属第二医院肿瘤放射治疗科 苏州大学肿瘤放射治疗学研究所 苏州市肿瘤放射治疗学重点实验室  
徐波 35205 美国阿拉巴马州伯明翰市南方研究院肿瘤系 bxu@uab.edu 
摘要点击次数: 2750
全文下载次数: 2438
中文摘要:
      恶性肿瘤发生、发展的每一个阶段均与免疫系统密切相关,而肿瘤细胞也常常利用程序性死亡蛋白-1通路等免疫调节检查点成功逃避免疫系统的攻击。目前,一些靶向于程序性死亡蛋白-1通路的免疫治疗药物已进入临床。过去,放疗一度被认为是一种局部性的免疫抑制性肿瘤治疗手段。最近,越来越多的证据表明,放疗更可能是一种全身性的免疫刺激性肿瘤治疗手段,因而靶向于程序性死亡蛋白-1通路的免疫治疗与放疗之间可能会存在协同作用从而产生强大的抗肿瘤疗效。本文旨在探讨目前放疗联合PD-1/PD-L1通路肿瘤免疫治疗领域内取得的新进展、面临的挑战以及未来的发展方向。
英文摘要:
      Every stage of tumor initiation and development closely relates to immune regulation as tumor cells tend to evade attacks from immune system by employing the programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) interaction. Therefore, targeting the PD-1/PD-L1 pathway has become an attractive approach for cancer immunotherapy. Radiotherapy has long been considered a local tumor treatment modality and it is immune-inhibitory. However, accumulated evidence has shown that radiotherapy might enhance immune function by eliminating the tumor mass and has become a systemic tumor treatment modality. These observations indicate a strong rationale that the radiotherapy and anti-PD-1 and anti-PD-L1 immunotherapy may work synergistically to provide a powerful anti-tumor effect. This review discusses current progresses, challenges and perspectives of this novel combination treatment modality.
HTML  查看全文  查看/发表评论  下载PDF阅读器
关闭